To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-04-14

Study Completion Date

2019-06-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this trial is to investigate the safety and tolerability of TAEST16001（TCR Affinity Enhancing Specific T cell Therapy）in the multi-line treatment failed advanced solid tumors except non small cell lung cancer,including liver cancer,gastric cancer,esophageal cancer,bone and soft tissue tumors,breast cancer, bladder carcinoma,prostate carcinoma,thyroid cancer, ovarian cancer and so on. The patients must meet the two criteria: human leukocyte antigens (HLA)-A\*0201+ and NY-ESO-1 positive cells≥25% by immunohistochemistry.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

NCT06478251

Tumor, Solid

RECRUITING PHASE1

Phase I Clinical Study of YK1101 Injection for the Treatment of Advanced Solid Tumors

NCT07139067

Advanced Solid Tumor Cancer

RECRUITING PHASE1

KSX01-TCRT Injection Project in Solid Tumors

NCT05811975

TCR-T Cells Refractory Solid Tumors Relapsed Solid Tumors

RECRUITING EARLY_PHASE1

Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

NCT04008394

Adult T-Cell Lymphoma/Leukaemia Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma +3 more

UNKNOWN PHASE1

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

NCT03638206

B-cell Acute Lymphoblastic Leukemia Lymphoma Myeloid Leukemia +13 more

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

TCR-T cell therapy has made a breakthrough for tumors in recent years. Phase I/II trial of NY-ESO-1-specific TCR-T treatment for synovial sarcoma and melanoma, conducted by the Rosenberg team at the National Cancer Institute, showed that 61% Synovial cell sarcoma and 55% melanoma had benefits, without severe side effects found in T cell receptor (TCR) transduced T-Cell Immunotherapy. The US FDA has granted breakthrough TCR-T cell therapy for patients with inoperable or metastatic synovial sarcoma. The European Medicines Agency has also approved the same therapy to Priority Medicines(PRIME).

This clinical trial is mainly focused on cancer-testis antigen, because it is not expressed in normal cells. NY-ESO-1 antigen as one member of cancer-testis antigen, is commonly expressed in 10-50% of melanoma, lung, liver, esophageal, breast, prostate, bladder, thyroid and ovarian cancer cases, 60% of multiple myeloma cases, and 70-80% of synovial sarcoma. The NY-ESO-1 TCR cell therapy for synovial sarcoma and melanoma has benefited many patients, but its effect on other solid tumors is still unknown. So we plan to explore its efficacy in many types of solid tumors.

The trial is to investigate the safety and tolerability of TAEST16001 cell therapy in multi-line treatment failed advanced solid tumors except non small cell lung cancer,including liver cancer,gastric cancer,esophageal cancer,bone and soft tissue tumors,breast cancer, bladder carcinoma,prostate carcinoma,thyroid cancer, ovarian cancer and so on. The patients must meet the two criteria: HLA-A\*0201+ and NY-ESO-1 positive cells≥25% by immunohistochemistry.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cancer Stage IV Gastric Cancer Stage IV Esophageal Cancer, Stage IV Bone and Soft Tissue Tumors Breast Cancer Stage IV Bladder Carcinoma Stage IV Prostate Carcinoma Stage IV Thyroid Cancer Stage IV Ovarian Cancer Stage IV Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

a single-center, open, single (or fractional) dose of safety and tolerability

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAEST16001

Patients who meet the inclusion criteria receive TAEST16001treatment after lymphodepleting by fludarabine and cyclophosphamide.

Group Type EXPERIMENTAL

TAEST16001

Intervention Type DRUG

After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAEST16001

After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* sign an informed consent before undertaking any trial-related activities;
* ≥18 and ≤75 years old;
* Multi-line treatment failed Solid Tumors except non small cell lung cancer,including Liver Cancer,Gastric Cancer,Esophageal Cancer,Bone and Soft Tissue Tumors,Breast Cancer, Bladder Carcinoma,Prostate Carcinoma,Thyroid Cancer, Ovarian Cancer and so on diagnosed by licensed pathologist;
* multi-line treatment failed patients;
* with measurable lesions according to Response Evaluation Criteria In Solid Tumors1.1 or immune related response criteria standard;
* meet the two screening indicators: HLA-A\*0201+, NYESO-1+(≥25% by immunohistochemistry);
* Eastern Cooperative Oncology Group score 0-1;life expectancy is longer than 3 months;
* The patient did not receive anti-tumor therapy within 4 weeks before enrollment;
* A brain metastasis patient in a stable condition for one month after anti-tumor therapy can be included;
* left ventricular ejection fraction≥50%
* Lab test results meet the following requirements:

white blood cell count≥3.0×10\^9/L; absolute neutrophil count≥1.5 ×10\^9/L (No human granulocyte colony stimulating factor support); blood platelet≥75 ×10\^9/L; Hemoglobin≥10g/dL (No transfusion in the last 7 days); Prothrombin time or International normalized rate ≤1.5×normal upper limit, except taking anticoagulant therapy; thrombin time≤1.5×normal upper limit, except taking anticoagulant therapy; a 24-hour creatinine clearance rate≥60mL/ min; Aspartate transaminase / serum glutamic oxaloacetic transaminase≤2.5 ×upper limit of normal; Alanine aminotransferase/ serum glutamate pyruvate transaminase≤2.5 ×upper limit of normal; total bilirubin≤1.5×upper limit of normal (expect that the subject has Gilbert's syndrome).

* no pregnant women；female patients must use contraceptive measures during the study and prohibit any homosexual or heterosexual;
* The patients can regularly visit the research institutions for related tests, evaluations, and management during the study period.

Exclusion Criteria

* lung cancer ;
* received major surgery, conventional chemotherapy, large-area radiotherapy, immune therapy or any biological anti-tumor therapy 4 weeks before enrollment;
* allergic to ingredients in this trial;
* common terminology criteria for adverse events ≥2 because of the previous surgery or treatment-related adverse reactions;
* with two types of primary solid tumors;
* poorly managed hypertension (systolic blood pressure \>160 mmHg and / or diastolic blood pressure \> 90 mmHg) or clinically serious (for example, active) cerebrovascular diseases such as cerebrovascular incident (within 6 months prior to signing the informed consent), myocardial infarction (within 6 months prior to signing the informed consent), unstable angina, grade II or above heart failure according to New York Heart Association Grading Congestive, or severe arrhythmia can not be controlled by medication or has a potential impact on the study; with consecutive three times of obvious abnormality on electrocardiogram or average QT corrected interval ≥450 millisecond;
* combined with other serious organic and mental disorders;
* serious or active bacteria, viral or fungal infections that require systemic treatment;
* with autoimmune diseases: such as a history of inflammatory bowel disease or other autoimmune diseases determined by the investigator as unsuitable for the study (e.g. systemic lupus erythematosus,vasculitis, invasive pulmonary disease);
* within 4 weeks prior the infusion, received chronic systemic steroid cortisone, hydroxyurea, immunomodulatory treatment (for example: Interleukin 2, alpha or gamma interferon, granulocyte colony stimulating factor, mammalian target of rapamycin inhibitors, cyclosporine, Thymosin etc);
* with organ transplantation, autologous/allogeneic stem cell transplantation and renal replacement therapy;
* with central nervous system metastasis but not receive treatment;
* with uncontrolled diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease, or liver failure;
* alcohol and / or drug abuse;
* pregnant or lactating women;
* received concomitant medication prohibited by this trial;
* with any medical condition or disease determined by the investigators that may be detrimental to this trial;
* without legal capacity / limited behavior.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No